BEUDAMED
    FDA Adverse Event Injury Summary report: N

    BILT3 BILIRUBIN TOTAL GEN.3

    MDR report key: 7138545 · Received December 21, 2017

    Report

    Report Number
    1823260-2017-03088
    Event Type
    Injury
    Date Received
    December 21, 2017
    Date of Event
    November 5, 2017
    Report Date
    January 5, 2018
    Manufacturer
    ROCHE DIAGNOSTICS
    Product Code
    CIG
    PMA / PMN Number
    K131544
    Removal / Correction Number
    NA
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    CA
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL

    Narratives

    Additional Manufacturer Narrative · 1

    THE EMPLOYEE GAVE BIRTH AT 27 WEEKS OF GESTATION. THE BIRTH WAS AN EMERGENCY CESAREAN SECTION. THE EMPLOYEE WAS IN PAIN, BUT THE DETAILS OF THE PAIN ARE NOT KNOWN. IT WAS NOT KNOWN IF THE EMPLOYEE WAS EXPOSED TO CHEMICAL REAGENTS WHILE PREGNANT. IN THE COURSE OF HER DAILY ROUTINE, THE EMPLOYEE WORE GLOVES AND A LABORATORY COAT TO LOAD/UNLOAD CK, TBIL, AND FOLRBC REAGENTS. THE EMPLOYEE POURED RESIDUAL REAGENTS OUT OF THE CONTAINER BEFORE DISCARDING THE CONTAINER INTO RECYCLING.

    Additional Manufacturer Narrative · 1

    THE CUSTOMER HAS 3 MODULAR PRE-ANALYTICS SYSTEMS AND EACH IS CONNECTED TO 3 MODULAR ANALYTICS P MODULE ANALYZERS, 3 MODULAR ANALYTICS E170 ANALYZERS, 1 COBAS 6000 C (501) MODULE,1 COBAS INTEGRA 800 ANALYZER, AND 3 COBAS C513 ANALYZERS. THE SERIAL NUMBERS OF THE ANALYZERS WERE NOT PROVIDED. ASIDE FROM SAFETY INFORMATION DOCUMENTED IN THE MATERIAL SAFETY DATA SHEET FOR EACH PRODUCT, THE OPERATOR IS INSTRUCTED TO FOLLOW SAFETY PRECAUTIONS PROVIDED IN THE OPERATOR'S MANUAL LABELING. THE SAFETY PRECAUTIONS INCLUDE: -WHEN HANDLING REAGENTS OR OTHER SOLUTIONS, EXERCISE THE PRECAUTIONS REQUIRED FOR HANDLING LABORATORY REAGENTS. BE SURE TO WEAR PROTECTIVE EQUIPMENT (SUCH AS GOGGLES, GLOVES). - OBSERVE THE CAUTIONS GIVEN IN THE PACKAGE INSERT AND OBSERVE THE INFORMATION GIVEN IN THE MATERIAL SAFETY DATA SHEETS AVAILABLE FOR ROCHE DIAGNOSTICS REAGENTS AND CLEANING SOLUTIONS. - BE CAREFUL WHEN REMOVING OPEN REAGENT PACKS FROM THE INSTRUMENT. THEY MAY CONTAIN RESIDUES OF REAGENTS. - AVOID DIRECT CONTACT WITH CLEANCELL M, SYSCLEAN, PROBEWASH M, OR HITERGENT. - IF A REAGENT, DETERGENT OR OTHER WORKING SOLUTION COMES INTO CONTACT WITH YOUR SKIN, WASH IT OFF IMMEDIATELY WITH WATER AND APPLY A DISINFECTANT. CONSULT A PHYSICIAN. - OBSERVE THE SYSTEM SAFETY LABELS ILLUSTRATED IN SAFETY LABELS SECTION OF THE SYSTEM OPERATOR'S MANUAL. THE CUSTOMER DID NOT PROVIDE ANY ADDITIONAL INFORMATION IN RELATION TO THE EVENT. THE CAUSE OF INTRAUTERINE DEATH REMAINS UNCLEAR. WITH SUCH LIMITED INFORMATION, NO MEDICAL ASSESSMENT WAS POSSIBLE. THE LABELING OF THE REAGENTS USED BY THE CUSTOMER FOLLOWED INTERNATIONAL RULES AND INDICATED POTENTIALLY TOXIC SUBSTANCES ADEQUATELY.

    Additional Manufacturer Narrative · 1

    THIS EVENT OCCURRED IN (B)(6).

    Description of Event or Problem · 1

    THE CUSTOMER STATED THAT AN EMPLOYEE AT THE SITE WAS WORKING ON A BENCH WITH REAGENTS SUPPLIED BY ROCHE. THE EMPLOYEE GAVE BIRTH TO A STILL BORN CHILD. THE EMPLOYEE AND THE EMPLOYEE'S DOCTOR HAVE CONCERNS THAT THE CHEMICALS SUPPLIED BY ROCHE MAY DAMAGE FERTILITY OR CAUSE HARM TO AN UNBORN CHILD. THE CUSTOMER WAS CONCERNED ABOUT EXPOSURE TO THE FOLLOWING REAGENTS: CK CREATINE KINASE LIQUID, ACC. TO IFCC (CK), BILT3 BILIRUBIN TOTAL GEN.3 (TBIL), AND THE ELECSYS FOLATE RBC ASSAY (FOLRBC). THESE REAGENTS WERE IDENTIFIED AS HAVING HEALTH HAZARD PICTOGRAMS WITH HAZARD STATEMENTS RELATING TO RISK OF DAMAGE TO FERTILITY OR THE UNBORN CHILD IN PRODUCT LABELING (PACKAGE INSERT). THIS MEDWATCH WILL APPLY TO THE TBIL ASSAY. PATIENT IDENTIFIERS FOR THE OTHER MENTIONED PRODUCTS: PT- (B)(6) = CK ; PT- (B)(6) = FOLRBC . NO FURTHER PATIENT DETAILS WERE PROVIDED AND THE DATE OF THE EVENT WAS NOT PROVIDED. ADDITIONAL DETAILS REGARDING THE EVENT AND THE PATIENT HAVE BEEN REQUESTED IN 2 FOLLOW-UPS WITH THE CUSTOMER. ADDITIONAL ATTEMPTS TO OBTAIN MORE INFORMATION WILL BE MADE. INFORMATION REGARDING PERSONAL PROTECTIVE EQUIPMENT USE BY THE EMPLOYEE HAS BEEN REQUESTED BUT NOT PROVIDED. INHALATION OF THE OF THE COMPLAINED REAGENTS IS NOT LIKELY DUE TO HIGH BOILING POINTS AND LOW VAPOR PRESSURE FOR THE SUBSTANCES OF CONCERN. TRANSCUTANEOUS ABSORPTION OF THE REAGENTS COULD NOT BE EXCLUDED, BUT SKIN CONTACT SHOULD BE PREVENTED WHEN SAFETY INSTRUCTIONS DOCUMENTED IN PRODUCT LABELING ARE FOLLOWED AND PERSONAL PROTECTIVE EQUIPMENT ARE WORN BY THE USER. THE REAGENT 1 BOTTLE OF THE TBIL REAGENT CONTAINS TETRAHYDROTHIOPHENE 1,1-DIOXIDE (4%), WHICH IS DOCUMENTED AS A HAZARDOUS SUBSTANCE. IT WAS ALSO NOTED THE CUSTOMER USES REAGENTS FROM VARIOUS OTHER MANUFACTURERS.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    919725 BILT3 BILIRUBIN TOTAL GEN.3 DIAZO COLORIMETRY, BILIRUBIN CIG ROCHE DIAGNOSTICS NA ASKU

    Patients

    Seq Age Sex Outcome Treatment
    1 43 YR Congenital Anomaly